Mark Emalfarb
Fortune : 4 M $ au 31/05/2026
Fortune : 4 M $ au 31/05/2026
Mark A. Emalfarb is the founder of Dyadic International, Inc., founded in 1979, holding the title of Chief Executive Officer & Director.
Current jobs include Chairman & Chief Executive Officer at Dyadic International (USA), Inc., and Director at Biotechnology Development for Industry in Pharmaceuticals SLU since 2017.
Education includes an undergraduate degree from the University of Iowa, conferred in 1977.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
DYADIC INTERNATIONAL, INC. 13,26 % | 24/04/2026 | 4 832 667 ( 13,26 % ) | 4 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| DYADIC INTERNATIONAL, INC. | Fondateur | 01/01/1979 |
Dyadic International (USA), Inc.
Dyadic International (USA), Inc. BiotechnologyHealth Technology Researches and manufactures genes | Directeur Général | 05/10/2011 |
Biotechnology Development for Industry in Pharmaceuticals SLU
Biotechnology Development for Industry in Pharmaceuticals SLU Miscellaneous Commercial ServicesCommercial Services Operates as an biotechnology company which produces recombinant proteins | Directeur/Membre du Conseil | 13/09/2017 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Dyadic International, Inc.
Dyadic International, Inc. Medical/Nursing ServicesHealth Services Manufactures genes and other biological products | Health Services |
University of Iowa
University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dyadic International (USA), Inc.
Dyadic International (USA), Inc. BiotechnologyHealth Technology Researches and manufactures genes | Health Technology |
Biotechnology Development for Industry in Pharmaceuticals SLU
Biotechnology Development for Industry in Pharmaceuticals SLU Miscellaneous Commercial ServicesCommercial Services Operates as an biotechnology company which produces recombinant proteins | Commercial Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national